health
Weight-loss wars go global as Novo Nordisk bets big on its Wegovy pill
The weight loss pill had a strong U.S. launch this year, and Novo believes that will be replicated in other markets around the world.
TL;DR
- Novo Nordisk is preparing to launch its Wegovy weight-loss pill globally, aiming for a significant international market presence.
- The company expects launches outside the U.S. later this year, pending regulatory approvals.
- Emil Kongshøj Larsen, Novo's Executive Vice President for International Operations, stated they will 'go all in' on the launch.
- The U.S. market currently accounts for over half of sales for both Novo Nordisk and rival Eli Lilly.
- Novo will consider factors like patient interest, doctor training, and telehealth availability when selecting launch countries.
- Telehealth has been identified as a key enabler for patient access to treatments in markets like Germany.
- Novo forecasts a sales decline of 4-12% in 2026, impacted by U.S. pricing and generic competition in countries like India, Canada, Brazil, and China.
- Despite overall forecasts, Wegovy's U.S. launch has exceeded expectations, with over 2 million total prescriptions.
- Eli Lilly's rival pill, Foundayo, launched with over 20,000 users but has recorded fewer prescriptions than Wegovy in comparable periods.
- Both Novo and Lilly believe their respective pills are expanding the overall weight-loss market rather than just cannibalizing injectable sales.
- The pill format is considered highly appealing to patients, and Novo expects 'superior efficacy' to drive international adoption.
- International launches may see a different uptake curve compared to the U.S., influenced by price differences with injectable versions.
- Analysts suggest potential early European markets for Wegovy include the UK, Germany, and Denmark.
- Novo anticipates significant growth from cash-paying customers, even in countries with socialized healthcare systems.
- Eli Lilly reported strong international revenue growth, indicating a global appetite for weight-loss medications.
- Pricing policies, such as the U.S. most-favored-nation policy, and European government approaches to drug pricing are key considerations for global launches.